Core Viewpoint - The article emphasizes the effectiveness of investing in dividend growth stocks and reinvesting dividends as a strategy for long-term wealth growth [1]. Group 1: Investment Strategy - The individual investor has explored various investment styles over 25 years, concluding that dividend growth stocks are particularly beneficial for wealth accumulation [1]. - The investor operates a blog focused on S&P Dividend Aristocrats and other dividend growth stocks, indicating a commitment to sharing knowledge in this investment area [1]. Group 2: Personal Investment Position - The analyst has disclosed a beneficial long position in shares of specific companies, indicating a personal investment interest that may influence their analysis [2]. - The article expresses the author's personal opinions and clarifies that they are not receiving compensation from any mentioned companies, ensuring transparency in their investment perspective [2].

In this article, we will take a look at the 13 Best Long-Term Dividend Stocks to Invest in Right Now.According to a recent report by WisdomTree, dividend growth is not a one-size-fits-all concept. Differences in sector exposure, profitability, and earnings growth expectations play a major role in shaping long-term results. In stable markets, these differences may seem less noticeable. During periods of volatility, their impact becomes much more visible.Investors who worry about valuation risk often focus on ...

Core Insights - The article highlights five US blue-chip companies that have consistently paid dividends for over 100 years, indicating their financial durability and strong management practices [1][2]. Company Summaries - **Coca-Cola (NYSE: KO)**: Founded in 1892, Coca-Cola has paid dividends since 1893, currently yielding 2.58%. It is the world's largest beverage company with over 500 brands and serves more than 1.9 billion servings daily across 200 countries. Morgan Stanley rates it Overweight with a target price of $87 [1][2]. - **Colgate-Palmolive (NYSE: CL)**: This consumer staples giant has paid dividends since 1895, yielding 2.14%. The company focuses on Oral Care, Personal Care, Home Care, and Pet Nutrition, selling products under various well-known brands. Goldman Sachs has a Buy rating with a target price of $100 [1][2]. - **Eli Lilly (NYSE: LLY)**: A healthcare company that has paid dividends since 1885, currently yielding 0.59%. Eli Lilly develops and markets pharmaceutical products, including those for cardiometabolic health and oncology. Barclays rates it Overweight with a target price of $1,350 [2]. - **Exxon Mobil (NYSE: XOM)**: This integrated oil and gas company has paid dividends since 1882, with a current yield of 2.67%. Exxon is a leader in crude oil and natural gas production and has a strong capital allocation strategy. UBS has a Buy rating with a target price of $171 [2]. - **Stanley Black & Decker (NYSE: SWK)**: The largest tool company globally, it has paid dividends for over 145 years, currently yielding 3.68%. The company offers a wide range of tools and accessories and is expected to benefit from a potential economic slowdown. Citigroup has a Buy rating with a target price of $100 [2].

Key Takeaways Procter & Gamble posted 1% y/y sales growth in Q2, with strength in Beauty and Health Care.Colgate delivered 2.2% y/y organic sales growth in Q2, driven by pricing and oral care leadership.CL's 2026 estimates show faster EPS growth, while PG trades below its 5-year median P/E.In the global consumer staples arena, The Procter & Gamble Company (PG) and Colgate-Palmolive Company (CL) represent two distinct models of market leadership. PG operates as a diversified powerhouse, commanding a strong m ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 (State or other jurisdiction of incorporation or organization) 300 Park Avenue ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 1-644 COLGATE-PALMOLIVE COMPANY (Exact name of registrant a ...

Key Takeaways Intellia Therapeutics has surged 57.2% in 12 weeks, outperforming the S&P 500's 5.6% rise.Getty Realty jumped 14.5% since Dec. 24 after being upgraded to a Zacks Rank #2.Colgate-Palmolive gained 20.6% in 12 weeks as part of the ECAP portfolio.Last Friday, the three most widely followed benchmark indexes closed a winning week. The Nasdaq Composite, the S&P 500 and the Dow Jones Industrial Average advanced 1.5%, 1.1% and 0.3%, respectively.The rally was driven by improving investor sentiment fol ...

Goldman Sachs maintains a "Buy" rating for NYSE:CL, raising the price target from $94 to $100.The company showcased its strategic initiatives at the Consumer Analyst Group of New York Conference 2026, boosting investor confidence.With a market capitalization of approximately $76.65 billion and a trading volume of 3,562,948 shares, Colgate-Palmolive demonstrates significant market presence and investor interest.Colgate-Palmolive Company (NYSE:CL) is a global leader in consumer products, specializing in oral ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Colgate-Palmolive Company (NYSE:CL) 2026 Conference February 20, 2026 08:00 AM ET Company ParticipantsCaroline Chulick - SVP of Global Growth and InnovationDara Mohsenian - Managing DirectorNoel Wallace - Chairman, President, and CEONone - Video Narrator 1None - Video Narrator 2None - Video Narrator 3None - Video Narrator 4None - Video Narrator 5None - Video Narrator 6Conference Call ParticipantsAndrea Teixeira - Managing Director and Senior Equity Research AnalystModeratorGood morning, everyone, and welcom ...

Consumer Analyst Group of New York Conference February 20, 2026 © 2026 Colgate-Palmolive Company TEAM NAME February 2026 Notice for Investor Presentation Please review the following presentation in conjunction with our fourth quarter and full year 2025 earnings press release, our fourth quarter and full year 2025 prepared management remarks and additional information regarding our non-GAAP financial measures, including GAAP to non- GAAP reconciliations, which are available in the Investor Center section of ...